Treatment of Diabetic Foot Ulcers With Inforatio Technique to Promote Wound Healing
NCT ID: NCT03985306
Last Updated: 2019-10-30
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
12 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-03-20
Study Completion Date
2019-09-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This trial will examine the feasibility of conducting a definitive randomized clinical trial that tests whether inforatio technique will reduce time to healing of diabetic foot ulcers. Inforatio technique is a procedure where small punch biopsies are taken from the wound bed near the edge of the wound. With this technique, the investigators wish to initiate an acute inflammatory response that increases the generation of granulation tissue with subsequent healing by scar formation. Thus, the investigators hypothesize that inforatio technique will promote healing of diabetic foot ulcers.
Based on clinical experience, the investigators have previously detected a reduction in time to healing as an unexpected effect when multiple punch biopsies are taken from the wound bed of diabetic foot ulcers. To the knowledge of the investigators, methods similar to the inforatio technique has not previously been studied.
Based on clinical experience, the investigators have previously detected a reduction in time to healing as an unexpected effect when multiple punch biopsies are taken from the wound bed of diabetic foot ulcers. To the knowledge of the investigators, methods similar to the inforatio technique has not previously been studied.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inforatio Technique to Promote Wound Healing of Diabetic Foot Ulcers
NCT05189470
Diabetic Foot Ulcer
Diabetes
Foot Ulcer
+3 more
ACTIVE_NOT_RECRUITING
NA
Timing of Revascularization in Patients With Diabetic Foot Ulcer and Non-critical Peripheral Artery Disease
NCT04939038
Diabetic Foot Ulcer
TERMINATED
NA
Effect of New High Ankle Block on Wound Healing After the Operation of Debridement of Diabetes Foot
NCT06395961
Wound Heal
Diabetic Foot Ulcer
ENROLLING_BY_INVITATION
NA
Treatment Study of Negative Pressure Wound Therapy for Diabetic Foot Wounds
NCT01480362
Foot Ulcer, Diabetic
COMPLETED
NA
Negative Pressure Wound Therapy in the Management of Diabetic Foot Ulcers
NCT04093635
Diabetic Foot Ulcer
UNKNOWN
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
BACKGROUND
The prevalence of diabetic foot ulcers is expected to increase considerably due to a continuously increasing prevalence of diabetes. The healing process of diabetic foot ulcers is complicated by a complex pathophysiology of the distal lower extremities and a constant exposure to bacteria and pressure. Improving healing of diabetic foot ulcers will have several benefits including higher quality of life, reduced morbidity, reduced mortality and lower socioeconomic costs. Nonetheless, there are few randomized controlled clinical trials on surgical and non-surgical treatment chronic foot ulcers and many studies on the topic have a low level of evidence.
TRIAL AIMS
The investigators aim to assess the feasibility of conducting a definitive randomized controlled trial by exploring recruitment, patient acceptability, protocol adherence and adverse effects.
The success criteria of the trial is as follows:
* Weekly recruitment rates at two patients or more.
* Time from first outpatient visit to recruitment at 21 days or less.
* Retention rate at 90-day follow-up at 50% or more
* No appearance of unacceptable adverse effects In addition, the trial aims to assess logistic concerns regarding the trial and to improve the method of inforatio application.
Based on findings from the feasibility trial, the investigators may amend the design of the definitive trial.
RECRUITMENT
Patients are eligibility-screened and identified by the primary investigator and wound care staff when patients visit wound outpatient clinics at the recruiting facilities.
INCLUSION AND FOLLOW-UP
Eligible patients are included if they give their oral and written consent to participate. The baseline trial visit take place on the day that patients give their consent to participate.
The trial comprises a 90-day clinical follow-up. Follow-up visits will be at 10, 21, 42 and 90 days after baseline (give or take 3 days). Wounds are assessed at each trial visit. The inforatio technique is applied at baseline and again at the 21-follow-up day if the wound still has a diameter larger than four mms. Participants unable to attend at the precise dates for midtrial follow-up will be eligible for follow-up three days before or after the intended date. The participants who cannot attend during this window will skip the follow-up day in concern. If the participants miss the second intervention at the 21-day follow-up, they are excluded. For the 90-day follow-up, participants are recalled two times by the primary investigator within two weeks before being excluded.
Participants exit from the trial if following occurs during follow-up:
* they undergo surgeries described in the exclusion criteria
* they get acute signs of infection, gangrene or osteomyelitis in their foot in concern
* their tendons, joints or bone become exposed in the wound bed
* they develop an acute phase of charcot arthropathy in their foot in concern
* they get admitted for reasons related to their foot ulcer
* they die or emigrate
The trial is stopped if the intervention shows an unintended effect or potential harm.
TRIAL STANDARD TREATMENT
The participants receive a trial standard treatment at every trial visit. The treatment is conducted by the primary investigator in cooperation with wound care nurses and podiatrists. The standard treatment is defined based on Danish National guidelines, local guidelines of the recruiting facilities and guidelines of the National Institute for Health and Care Excellence.
The treatment is based on a flowchart that individualizes treatment based on clinical wound characteristics.
INFORATIO TECHNIQUE
The technique is described in the Arms and Interventions section.
TRIAL MEASURES
Wound assessment: Wounds are assessed at every trial visit. To monitor the ulcer area during follow-up, the investigators will analyze digital photos of the ulcer by using Image J which is a wound planimetry software. The depth of the ulcers are measured with sterile wound probes and reported by intervals of 5 millimeters. Undermining will be assessed with the same method as for depth and in intervals of 5 millimeters.
Microbial samples: At both stages of inforatio application, three punch biopsies are sent for cultivation to analyze bacterial species, bacterial load and resistance patterns of the bacteria.
Patient and staff interviews: described in the Outcome Measures section
STATISTICAL ANALYSIS
With descriptive statistics participants' demographics, the quantitative success criteria, the quantitative outcome measures and time to healing will be reported. Clinical healing is defined by intact epithelia.
The investigators will use statistical software SPSS version 21.0 (IBM Corp., Armonk, New York).
SAMPLE SIZE CONSIDERATION
Because effectiveness is not evaluated, a formal power calculation is not considered necessary for the objectives of a feasibility trial.
To minimize the number of patients that are exposed to a new intervention meanwhile keeping a level of precision for the variance estimate, the rule of thumb by Julious et al will be used for determination of the trial sample size. Thus, 12 participants will be included in the trial. Julious et al argues that a sample size of 12 per group gives a sufficient precision of the mean and variance estimates. Other studies report rules of thumbs with larger sample size to gain sufficient power for a pilot or feasibility trial.
ETHICAL CONSIDERATIONS AND RISK ASSESSMENT OF SIDE EFFECTS
The procedure of the intervention is small with an expectedly small risk of harm outcomes. The punch biopsies from the inforatio technique is relatively shallow therefore it is not expected that it will penetrate important anatomical structures or expose bone.
The primary investigator's clinical assessment, patient preference and patient tolerance is taken into consideration before inforatio technique is applied. Minimal discomfort is expected for the participants when they receive the inforatio technique treatment. Previous applications by the investigators showed that patients reported no or little pain during application.
The inforatio technique treatment has previously shown potential to improve healing thus participants may gain an improvement in healing of their foot ulcers.
If this trial shows that a definitive randomised clinical trial will be feasible, the investigators will examine the effect of inforatio technique through a larger randomised clinical trial. If the inforatio technique shows significant positive effect on time to healing it would become of great importance for future diabetic foot ulcer patients. The inforatio technique would become an addition to available therapeutic options. The technique is simple and only requires a punch biopsy tool. Nurses and general practitioners can be potential applicants that apply the treatment at clinics close to patient habitats making visits for wound treatment more convenient for the patients. If there is a significant positive effect on healing, it is expected that it will result in reduction of hospital admissions and less surgical interventions including amputations.
This project may contribute to more focus on treatment of patients with diabetic foot ulcers - a field of research that still needs studies to enable evidence-based treatment.
Inspectors from The National Committee of Health Research Ethics will have the authorization to quality control the trial.
COMPETING INTERESTS
The trial investigators declare that they have no competing interests.
The prevalence of diabetic foot ulcers is expected to increase considerably due to a continuously increasing prevalence of diabetes. The healing process of diabetic foot ulcers is complicated by a complex pathophysiology of the distal lower extremities and a constant exposure to bacteria and pressure. Improving healing of diabetic foot ulcers will have several benefits including higher quality of life, reduced morbidity, reduced mortality and lower socioeconomic costs. Nonetheless, there are few randomized controlled clinical trials on surgical and non-surgical treatment chronic foot ulcers and many studies on the topic have a low level of evidence.
TRIAL AIMS
The investigators aim to assess the feasibility of conducting a definitive randomized controlled trial by exploring recruitment, patient acceptability, protocol adherence and adverse effects.
The success criteria of the trial is as follows:
* Weekly recruitment rates at two patients or more.
* Time from first outpatient visit to recruitment at 21 days or less.
* Retention rate at 90-day follow-up at 50% or more
* No appearance of unacceptable adverse effects In addition, the trial aims to assess logistic concerns regarding the trial and to improve the method of inforatio application.
Based on findings from the feasibility trial, the investigators may amend the design of the definitive trial.
RECRUITMENT
Patients are eligibility-screened and identified by the primary investigator and wound care staff when patients visit wound outpatient clinics at the recruiting facilities.
INCLUSION AND FOLLOW-UP
Eligible patients are included if they give their oral and written consent to participate. The baseline trial visit take place on the day that patients give their consent to participate.
The trial comprises a 90-day clinical follow-up. Follow-up visits will be at 10, 21, 42 and 90 days after baseline (give or take 3 days). Wounds are assessed at each trial visit. The inforatio technique is applied at baseline and again at the 21-follow-up day if the wound still has a diameter larger than four mms. Participants unable to attend at the precise dates for midtrial follow-up will be eligible for follow-up three days before or after the intended date. The participants who cannot attend during this window will skip the follow-up day in concern. If the participants miss the second intervention at the 21-day follow-up, they are excluded. For the 90-day follow-up, participants are recalled two times by the primary investigator within two weeks before being excluded.
Participants exit from the trial if following occurs during follow-up:
* they undergo surgeries described in the exclusion criteria
* they get acute signs of infection, gangrene or osteomyelitis in their foot in concern
* their tendons, joints or bone become exposed in the wound bed
* they develop an acute phase of charcot arthropathy in their foot in concern
* they get admitted for reasons related to their foot ulcer
* they die or emigrate
The trial is stopped if the intervention shows an unintended effect or potential harm.
TRIAL STANDARD TREATMENT
The participants receive a trial standard treatment at every trial visit. The treatment is conducted by the primary investigator in cooperation with wound care nurses and podiatrists. The standard treatment is defined based on Danish National guidelines, local guidelines of the recruiting facilities and guidelines of the National Institute for Health and Care Excellence.
The treatment is based on a flowchart that individualizes treatment based on clinical wound characteristics.
INFORATIO TECHNIQUE
The technique is described in the Arms and Interventions section.
TRIAL MEASURES
Wound assessment: Wounds are assessed at every trial visit. To monitor the ulcer area during follow-up, the investigators will analyze digital photos of the ulcer by using Image J which is a wound planimetry software. The depth of the ulcers are measured with sterile wound probes and reported by intervals of 5 millimeters. Undermining will be assessed with the same method as for depth and in intervals of 5 millimeters.
Microbial samples: At both stages of inforatio application, three punch biopsies are sent for cultivation to analyze bacterial species, bacterial load and resistance patterns of the bacteria.
Patient and staff interviews: described in the Outcome Measures section
STATISTICAL ANALYSIS
With descriptive statistics participants' demographics, the quantitative success criteria, the quantitative outcome measures and time to healing will be reported. Clinical healing is defined by intact epithelia.
The investigators will use statistical software SPSS version 21.0 (IBM Corp., Armonk, New York).
SAMPLE SIZE CONSIDERATION
Because effectiveness is not evaluated, a formal power calculation is not considered necessary for the objectives of a feasibility trial.
To minimize the number of patients that are exposed to a new intervention meanwhile keeping a level of precision for the variance estimate, the rule of thumb by Julious et al will be used for determination of the trial sample size. Thus, 12 participants will be included in the trial. Julious et al argues that a sample size of 12 per group gives a sufficient precision of the mean and variance estimates. Other studies report rules of thumbs with larger sample size to gain sufficient power for a pilot or feasibility trial.
ETHICAL CONSIDERATIONS AND RISK ASSESSMENT OF SIDE EFFECTS
The procedure of the intervention is small with an expectedly small risk of harm outcomes. The punch biopsies from the inforatio technique is relatively shallow therefore it is not expected that it will penetrate important anatomical structures or expose bone.
The primary investigator's clinical assessment, patient preference and patient tolerance is taken into consideration before inforatio technique is applied. Minimal discomfort is expected for the participants when they receive the inforatio technique treatment. Previous applications by the investigators showed that patients reported no or little pain during application.
The inforatio technique treatment has previously shown potential to improve healing thus participants may gain an improvement in healing of their foot ulcers.
If this trial shows that a definitive randomised clinical trial will be feasible, the investigators will examine the effect of inforatio technique through a larger randomised clinical trial. If the inforatio technique shows significant positive effect on time to healing it would become of great importance for future diabetic foot ulcer patients. The inforatio technique would become an addition to available therapeutic options. The technique is simple and only requires a punch biopsy tool. Nurses and general practitioners can be potential applicants that apply the treatment at clinics close to patient habitats making visits for wound treatment more convenient for the patients. If there is a significant positive effect on healing, it is expected that it will result in reduction of hospital admissions and less surgical interventions including amputations.
This project may contribute to more focus on treatment of patients with diabetic foot ulcers - a field of research that still needs studies to enable evidence-based treatment.
Inspectors from The National Committee of Health Research Ethics will have the authorization to quality control the trial.
COMPETING INTERESTS
The trial investigators declare that they have no competing interests.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Diabetic Foot Ulcer
Diabetic Foot
Wound Heal
Ulcer Foot
Ulcer Healing
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
The trial is a single-center single-group feasibility trial in outpatient clinical settings.
The trial will be reported with reference to the extended CONSORT guidelines.
The trial will be reported with reference to the extended CONSORT guidelines.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Feasibility trial group
Every trial patient will receive the intervention (the inforatio technique) that is intended for the definitive randomized clinical trial.
Group Type
EXPERIMENTAL
Inforatio technique
Intervention Type
PROCEDURE
We define the inforatio technique as punch biopsies taken in the periphery of the wound bed. The punch biopsies will have a diameter of two mms. The depth of the biopsies is primarily based on clinical assessment on distance to bone by assessment with a sterile wound probe and with attention to location and anatomy. The maximum depth will be 3.5 millimeters. The biopsies will be taken from one to two mms from the wound edges and with a distance of five mms between the biopsies.
Inforatio technique is applied after standard care and wound assessment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Inforatio technique
We define the inforatio technique as punch biopsies taken in the periphery of the wound bed. The punch biopsies will have a diameter of two mms. The depth of the biopsies is primarily based on clinical assessment on distance to bone by assessment with a sterile wound probe and with attention to location and anatomy. The maximum depth will be 3.5 millimeters. The biopsies will be taken from one to two mms from the wound edges and with a distance of five mms between the biopsies.
Inforatio technique is applied after standard care and wound assessment.
Intervention Type
PROCEDURE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
We include diabetic patients with foot ulcers that are more than six weeks old and which are located distal to the malleoli.
The diameters of the ulcers must be at least four mms. One wound from each foot of a patient can be included. If a patient's foot have more than one ulcer that meets the abovementioned criteria, the biggest wound is included. If there is no difference in size, the wound that has the most recent onset is included. If two wounds are close to each other and separated by less than 5 mm intact skin, we will consider it as one wound.
Wound onset estimates will be patient-reported.
The diameters of the ulcers must be at least four mms. One wound from each foot of a patient can be included. If a patient's foot have more than one ulcer that meets the abovementioned criteria, the biggest wound is included. If there is no difference in size, the wound that has the most recent onset is included. If two wounds are close to each other and separated by less than 5 mm intact skin, we will consider it as one wound.
Wound onset estimates will be patient-reported.
Exclusion Criteria
We exclude following patients:
* Patients with dementia and other patients who are not able to give their informed consent.
* Patients with gangrene, necrosis deeper than 1mm, osteomyelitis and clinical signs of infection in their foot. Infection is identified by clinical assessment based on the classical signs comprising oedema, pain, warmth, redness and purulent exudates and is assessed by an experienced orthopedic surgeon.
* Patients with ulcers that have positive probe-to-bone test and visible joint and tendons
* Patients with systolic toe pressure of \< 20 mmHg
* Patients that, since the onset of their present foot ulcer, underwent vascular surgery in the lower extremity with the same laterality as the foot ulcer.
* Patients that, since the onset of their present foot ulcer, underwent surgical off-loading and amputations
* Patients that, since the onset of their present foot ulcer, underwent surgical wound revisions in an operating room.
* Patients that have an acute phase of Charcot arthropathy in the foot that presents with a foot ulcer.
* Patients that take systemic immunosuppressive drugs.
* Patients with cancer
* Patients with scleroderma
* Patients with dementia and other patients who are not able to give their informed consent.
* Patients with gangrene, necrosis deeper than 1mm, osteomyelitis and clinical signs of infection in their foot. Infection is identified by clinical assessment based on the classical signs comprising oedema, pain, warmth, redness and purulent exudates and is assessed by an experienced orthopedic surgeon.
* Patients with ulcers that have positive probe-to-bone test and visible joint and tendons
* Patients with systolic toe pressure of \< 20 mmHg
* Patients that, since the onset of their present foot ulcer, underwent vascular surgery in the lower extremity with the same laterality as the foot ulcer.
* Patients that, since the onset of their present foot ulcer, underwent surgical off-loading and amputations
* Patients that, since the onset of their present foot ulcer, underwent surgical wound revisions in an operating room.
* Patients that have an acute phase of Charcot arthropathy in the foot that presents with a foot ulcer.
* Patients that take systemic immunosuppressive drugs.
* Patients with cancer
* Patients with scleroderma
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zealand University Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sahar Moeini, MD
Role: PRINCIPAL_INVESTIGATOR
Zealand University Hospital Koege, Denmark
Hans Gottlieb, Chief consultant, MD PhD
Role: STUDY_CHAIR
Herlev University Hospital, Denmark
Tue S Jørgensen, MD PhD
Role: STUDY_CHAIR
Hvidovre University Hospital, Denmark
Malene RB Larsen, MD
Role: STUDY_CHAIR
Zealand University Hospital Koege, Denmark
Stig Brorson, Professor, MD PhD DMsc
Role: PRINCIPAL_INVESTIGATOR
Zealand University Hospital Koege, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Herlev University Hospital, Department of Orthopaedic Surgery
Herlev, , Denmark
Site Status
Zealand University Hospital, Department of Orthopaedic Surgery
Køge, , Denmark
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Denmark
References
Explore related publications, articles, or registry entries linked to this study.
Andrews KL, Houdek MT, Kiemele LJ. Wound management of chronic diabetic foot ulcers: from the basics to regenerative medicine. Prosthet Orthot Int. 2015 Feb;39(1):29-39. doi: 10.1177/0309364614534296.
Reference Type
BACKGROUND
Karri VV, Kuppusamy G, Talluri SV, Yamjala K, Mannemala SS, Malayandi R. Current and emerging therapies in the management of diabetic foot ulcers. Curr Med Res Opin. 2016;32(3):519-42. doi: 10.1185/03007995.2015.1128888. Epub 2016 Jan 12.
Reference Type
BACKGROUND
Zimny S, Pfohl M. Healing times and prediction of wound healing in neuropathic diabetic foot ulcers: a prospective study. Exp Clin Endocrinol Diabetes. 2005 Feb;113(2):90-3. doi: 10.1055/s-2004-830537.
Reference Type
BACKGROUND
Greer N, Foman N, Dorrian J, Fitzgerald P, MacDonald R, Rutks I, Wilt T. Advanced Wound Care Therapies for Non-Healing Diabetic, Venous, and Arterial Ulcers: A Systematic Review [Internet]. Washington (DC): Department of Veterans Affairs (US); 2012 Nov. Available from http://www.ncbi.nlm.nih.gov/books/NBK132238/
Reference Type
BACKGROUND
Game FL, Apelqvist J, Attinger C, Hartemann A, Hinchliffe RJ, Londahl M, Price PE, Jeffcoate WJ; International Working Group on the Diabetic Foot. Effectiveness of interventions to enhance healing of chronic ulcers of the foot in diabetes: a systematic review. Diabetes Metab Res Rev. 2016 Jan;32 Suppl 1:154-68. doi: 10.1002/dmrr.2707.
Reference Type
BACKGROUND
Braun LR, Fisk WA, Lev-Tov H, Kirsner RS, Isseroff RR. Diabetic foot ulcer: an evidence-based treatment update. Am J Clin Dermatol. 2014 Jul;15(3):267-81. doi: 10.1007/s40257-014-0081-9.
Reference Type
BACKGROUND
Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016 Oct 24;355:i5239. doi: 10.1136/bmj.i5239.
Reference Type
BACKGROUND
Braun L, Kim PJ, Margolis D, Peters EJ, Lavery LA; Wound Healing Society. What's new in the literature: an update of new research since the original WHS diabetic foot ulcer guidelines in 2006. Wound Repair Regen. 2014 Sep-Oct;22(5):594-604. doi: 10.1111/wrr.12220.
Reference Type
BACKGROUND
SIGN. 116 Management of diabetes. A national clinical guideline. 2017; Available from: https://www.sign.ac.uk/assets/sign116.pdf
Reference Type
BACKGROUND
NICE Guideline. Diabetic foot problems: prevention and management [Internet]. [cited 2019 Jan 3]. Available from: https://www.nice.org.uk/guidance/ng19
Reference Type
BACKGROUND
Rogers LC, Bevilacqua NJ, Armstrong DG, Andros G. Digital planimetry results in more accurate wound measurements: a comparison to standard ruler measurements. J Diabetes Sci Technol. 2010 Jul 1;4(4):799-802. doi: 10.1177/193229681000400405.
Reference Type
BACKGROUND
Schweitzer ME, Daffner RH, Weissman BN, Bennett DL, Blebea JS, Jacobson JA, Morrison WB, Resnik CS, Roberts CC, Rubin DA, Seeger LL, Taljanovic M, Wise JN, Payne WK. ACR Appropriateness Criteria on suspected osteomyelitis in patients with diabetes mellitus. J Am Coll Radiol. 2008 Aug;5(8):881-6. doi: 10.1016/j.jacr.2008.05.002.
Reference Type
BACKGROUND
Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat [Internet]. 2005;4(4):287-91. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/pst.185
Reference Type
BACKGROUND
Cocks K, Torgerson DJ. Sample size calculations for pilot randomized trials: a confidence interval approach. J Clin Epidemiol. 2013 Feb;66(2):197-201. doi: 10.1016/j.jclinepi.2012.09.002. Epub 2012 Nov 27.
Reference Type
BACKGROUND
Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res. 2016 Jun;25(3):1057-73. doi: 10.1177/0962280215588241. Epub 2015 Jun 19.
Reference Type
BACKGROUND
O'Meara SM, Cullum NA, Majid M, Sheldon TA. Systematic review of antimicrobial agents used for chronic wounds. Br J Surg. 2001 Jan;88(1):4-21. doi: 10.1046/j.1365-2168.2001.01631.x.
Reference Type
BACKGROUND
Teare MD, Dimairo M, Shephard N, Hayman A, Whitehead A, Walters SJ. Sample size requirements to estimate key design parameters from external pilot randomised controlled trials: a simulation study. Trials. 2014 Jul 3;15:264. doi: 10.1186/1745-6215-15-264.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REG-122-2018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Assessment of the Efficacy and Tolerance of Sub-cutaneous Re-injection of Autologous Adipose-derived REGEnerative Cells in the Local Treatment of Neuropathic Diabetic Foot ulcERs
NCT02866565
NOT_YET_RECRUITING
PHASE2
Treatment of Chronic Wounds in Diabetic Foot Syndrome With Allogeneic Adipose Derived Mesenchymal Stem Cells
NCT03865394
COMPLETED
PHASE1/PHASE2
Diabetic Foot Ulcer Recurrence: Pilot Study
NCT03479242
TERMINATED
Treatment of Diabetic Foot Ulcers With AUP1602-C
NCT04281992
COMPLETED
PHASE1/PHASE2
Intensive Versus Conventional Glycemic Control in Diabetic Foot Ulcer Healing
NCT03740581
UNKNOWN
NA
Randomized Controlled Clinical Investigation Evaluating the Effect of Adipose Tissue Processed With the SyntrFuge™ System in the Healing of Diabetic Foot Ulcers
NCT05519501
COMPLETED
NA
Effect of Self- and Family Management of Diabetic Foot Ulcers Programs on Health Outcomes
NCT03909802
COMPLETED
NA
Effect of Adiposity and Associated Local Microbial Factors on Healing and Progression of Diabetic Foot Ulcers
NCT03960255
UNKNOWN
Evaluating the Healing of Diabetic Foot Ulcers With Compounded Anti-Infective Irrigation Therapy
NCT05076955
UNKNOWN
EARLY_PHASE1
Shockwave Treatment of Diabetic Foot Ulcer: Step I
NCT00954343
WITHDRAWN
NA
MIRODERM H2H DFU Study
NCT03232333
COMPLETED
Diabetes Related Foot Ulcers with Negative Pressure Wound Therapy
NCT06721754
RECRUITING
NA
Safety and Efficacy Study of an Interactive Wound Dressing (KC002) for the Treatment of Diabetic Foot Ulcers
NCT00330265
UNKNOWN
PHASE2
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
NCT02833389
COMPLETED
PHASE1
Effectiveness of the Autologous Adipose Tissue Harvested With SEFFICARE Method for Treatment of DFU Minor Amputation
NCT05072353
UNKNOWN
NA
Ulcer Location and Debridement Frequency: Weekly vs. Biweekly Sharp Debridement in Diabetic Foot Ulcers
NCT06160817
COMPLETED
NA
Examining the Effectiveness of DermGEN™ in the Treatment of Diabetic Foot Ulcers in First Nations People
NCT05251480
NOT_YET_RECRUITING
NA
A Dose Finding Study of Topically Applied I-020201 as an Adjunct to Good Standard-of-care in Patients With Chronic Diabetic Foot Ulcers
NCT00915486
COMPLETED
PHASE2
Nerve Decompression for Ulcer Recurrence Avoidance (DURA)
NCT01762085
UNKNOWN
NA
Efficacy of LL-37 Cream on Bacteria Colonization, Inflammation Response and Healing Rate of Diabetic Foot Ulcers
NCT04098562
UNKNOWN
PHASE2
Impaired Wound Healing in Diabetic Foot Ulceration
NCT00739323
COMPLETED
Diabetic Foot Ulcers: Shorter Treatment Period Using Custom Felt Relief?
NCT04058639
RECRUITING
NA
Wound Healing Effects of HO/03/03 In Patients With Diabetic Neuropathic Plantar and Venous Ulcers, Pilot Study.
NCT00338923
COMPLETED
PHASE1
Resorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers
NCT03398538
COMPLETED
NA
Cell Therapy for Diabetic Foot Ulcer
NCT05234086
UNKNOWN
PHASE2